Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
Validation of Type II Variation will allow Takeda to commence launches in Europe later this year The pre-filled syringe presentation…